Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PEGPH20 strikeout raises doubts about stroma-targeting agents in pancreatic cancer

Key clinical point: Adding pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel and gemcitabine (AG) did not improve survival in adults with previously untreated metastatic pancreatic ductal adenocarcinoma.

Major finding: The median overall survival was 11.2 months in patients who received PEGPH20 plus AG and 11.5 months in those who received placebo plus AG (hazard ratio, 1.00; P = .97).

Study details: Phase 3 trial of 492 adults with previously untreated, metastatic pancreatic ductal adenocarcinoma, 327 of whom were randomized to PEGPH20 plus AG and 165 of whom were randomized to placebo plus AG.

Disclosures: The study was funded by Halozyme. The authors reported various ties to Halozyme and many other companies.


Van Cutsem E et al. J Clin Oncol. 2020 Jul 24;JCO2000590. doi: 10.1200/JCO.20.00590.